Uric Acid and Hypertension in African-Americans
Uric Acid and Hypertension in African-Americans
批准号:
7105071
负责人:
Richard Joseph Johnson
金额:
$70.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-08-01 至 2009-04-30
关键词:
African Americanallopurinolblood flow measurementchlorothiazideclinical researchdata collection methodology /evaluationdisease /disorder prevention /controldosagedrug adverse effectglomerular filtrationglucose toleranceglucose tolerance testhigh performance liquid chromatographyhuman subjecthuman therapy evaluationhyperinsulinismhypertensionhypertriglyceridemiahyperuricemiainflammationkidney circulationliquid chromatography mass spectrometrymedical complicationmetabolic syndromepatient oriented researchradioimmunoassaytherapy adverse effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Thiazide diuretics are associated with many metabolic side effects including hyperuricemia, gout, insulin resistance, and hyperlipidemia. These very conditions are already highly prevalent in African-Americans. We and others have generated a large body of epidemiologic, animal model, cell culture, and preliminary data in patients that suggests that uric acid is itself a mediator of hypertension, endotheliai dysfunction, and systemic inflammation. In our animal models elevated uric acid leads to increased blood pressure (BP) and lowering uric acid decreases BP. Furthermore, our study of hypertensive young adults suggests that allopurinol treatment leads to a decrease in uric acid associated with a lower BP. Our hypothesis is that thiazide-induced hyperuricemia decreases the efficacy of thiazides in controlling BP, leads to endothelial dysfunction, and increases the incidence of insulin resistance and impaired glucose tolerance. This hypothesis will be tested in a randomized double-blind placebo-controlled 2x2 factorial clinical trial of 8- week duration in which a total of 300 African-Americans patients with stage 1 hypertension (BP: 140-159/90- 99 mm Hg) will be assigned to one of four regimens: 1) a thiazide-like diuretic, chlorthalidone 25 mg/day, and a xanthine oxidase inhibitor, allopurinol; 2) chlorthalidone 25 mg/day and placebo; 3) placebo or 4) allopurinol. All subjects will receive a low-sodium diet. Our hypothesis predicts that lowering uric acid will enhance BP control, prevent endothelial dysfunction, reduce systemic inflammation, improve g.ucose tolerance and reduce hyperinsulinemia. In Aim 1 we test the hypothesis that prevention of chlorthalidone - induced hyperuricemia with allopurinol results in improved BP control. In Aim 2 we test the hypothesis that prevention of chlorthalidone-induced increase in serum uric acid by allopurinol improves endothelial function and reduces systemic inflammation. In Aim 3 we test the hypothesis that prevention of chlorthalidone induced hyperuricemia with allopurinol improves renal blood flow and GFR and prevents microalbumineria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
-
批准号:10221502
-
项目类别:
-
资助金额:$123.33万
-
财政年份:2019
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
-
批准号:10441315
-
项目类别:
-
资助金额:$116.39万
-
财政年份:2019
-
负责人:Richard Joseph Johnson
-
依托单位:
A Novel Mechanism for Sarcopenia in Chronic Kidney Disease
-
批准号:10265352
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
-
批准号:10659119
-
项目类别:
-
资助金额:$115.2万
-
财政年份:2019
-
负责人:Richard Joseph Johnson
-
依托单位:
A Novel Mechanism for Sarcopenia in Chronic Kidney Disease
-
批准号:10454871
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
-
批准号:10022080
-
项目类别:
-
资助金额:$125.99万
-
财政年份:2019
-
负责人:Richard Joseph Johnson
-
依托单位:
Dietary Salt has an Unrecognized Role in Modulating Energy Intake and Metabolic Syndrome
-
批准号:9114329
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2016
-
负责人:Richard Joseph Johnson
-
依托单位:
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity
-
批准号:9464351
-
项目类别:
-
资助金额:$28.94万
-
财政年份:2015
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
-
批准号:9275427
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
-
批准号:8966551
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
-
批准号:9789159
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Richard Joseph Johnson
-
依托单位:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
-
批准号:8735238
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Richard Joseph Johnson
-
依托单位:
PROINFLAMMATORY ROLE OF URIC ACID IN LUNG DISEASE: NOVEL MODELS AND CLINICAL VALI
-
批准号:8606240
-
项目类别:
-
资助金额:$18.96万
-
财政年份:2013
-
负责人:Richard Joseph Johnson
-
依托单位:
PROINFLAMMATORY ROLE OF URIC ACID IN LUNG DISEASE: NOVEL MODELS AND CLINICAL VALI
-
批准号:8444228
-
项目类别:
-
资助金额:$23.14万
-
财政年份:2013
-
负责人:Richard Joseph Johnson
-
依托单位:
Development of inhibitors of AMP Deaminase Isoform 2 as a Mechanism for Treating
-
批准号:8046591
-
项目类别:
-
资助金额:$227.14万
-
财政年份:2010
-
负责人:Richard Joseph Johnson
-
依托单位:
Endothelial Cell in Progressive Renal Disease
-
批准号:7919178
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2009
-
负责人:Richard Joseph Johnson
-
依托单位:
Uric Acid and Hypertension in African-Americans
-
批准号:7271341
-
项目类别:
-
资助金额:$68.73万
-
财政年份:2005
-
负责人:Richard Joseph Johnson
-
依托单位:
Uric Acid and Hypertension in African-Americans
-
批准号:6964100
-
项目类别:
-
资助金额:$70.88万
-
财政年份:2005
-
负责人:Richard Joseph Johnson
-
依托单位:
Role of Uric Acid in Cardiovascular and Renal Disease
-
批准号:7475588
-
项目类别:
-
资助金额:$38.8万
-
财政年份:2002
-
负责人:Richard Joseph Johnson
-
依托单位:
Role of Uric Acid in Cardiovascular and Renal Disease
-
批准号:7802857
-
项目类别:
-
资助金额:$40.4万
-
财政年份:2002
-
负责人:Richard Joseph Johnson
-
依托单位:
国内基金
海外基金
Apocynin和allopurinol对运动上调自发性高血压大鼠肾脏一氧化氮合成酶表达的影响
-
批准号:81301667
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:曹鹏宇
-
依托单位: